WuXi Biologics WKN: A2QJCN ISIN: KYG970081173 Forum: Aktien User: Summer.76

Ist auch etwas länger, deshalb bei Interesse bitte eigenständig durch den Übersetzer jagen: Citigroup first awarded WuXi Biologics (02269.HK) "Buy" target price of 130 yuan in "The Big Bank Report" http://www.aastocks.com/tc/stocks/news/aafn-con/now.1070560/latest-news

Bank of Communications International: WuXi Biologics (02269-HK) continues to expand its production capacity and the demand for later projects surges, the first to buy https://www.finet.hk/newscenter/news_content/600776c8bde0b30d4618ee82 Bank of Communications International released a report that WuXi Biologics (02269-HK) 5-10 projects will enter the commercial manufacturing stage, and related orders totaling USD 700 million to 1 billion will be completed in 2021-22; In 2021-22, it will contribute US$200-400 million in CMO revenue; 3) The number of new projects per year will be increased from 40-50 to 60-80. Production capacity continues to expand, and total CMO production capacity will increase from 54,000 liters in 2020 to 125,000/280,000 liters in 2021/23. Due to the surge in demand for later projects, the bank expects that WuXi’s new plant will have a high utilization rate, and the staff team will increase by 2,000 from the current approximately 6,600. The bank raised its 2020-22 net profit forecast by 2-5% to reflect the revenue contribution of CMOs, and based on DCF, raised its target price from HK$86.33 to HK$122.08, reiterating that WuXi is the industry’s first buy.

WuXi Biologics and Oxford BioTherapeutics join forces on second bispecific program https://www.thepharmaletter.com/article/wuxi-biologics-and-oxford-biotherapeutics-join-forces-on-second-bispecific-program

https://doc.irasia.com/listco/hk/wuxibiologics/announcement/a210119.pdf WuXi Biologics (02269) hat aufgrund der Ausübung von Aktienoptionen insgesamt 6.146.800 Aktien ausgegeben https://m.jrj.com.cn/madapter/hk/2021/01/19223231724173.shtml WuXi Biologics (02269), gab bekannt, dass die Direktoren und Mitarbeiter des Unternehmens im Zeitraum vom 4. bis 19. Januar 2021 ihre Aktienoptionen im Rahmen des Aktienoptionsplans vor dem Börsengang ausgeübt und insgesamt neue Aktien ausgegeben haben 6,1468 Millionen Aktien.

Fand ihn auch klasse und sehr lesenswert

Super Artikel über WuXi im Kölner Stadtanzeiger😊👍🏼!!! Danke Summer.76 fürs Teilen🙏🏼

https://finance.sina.cn/hkstock/ggpj/2021-01-18/detail-ikftpnnx8713311.d.html?fromwap Zhongtai International daily morning news: ... We still recommend focusing on the current policy havens in the pharmaceutical industry-CXO, biotechnology, and Chinese medicine formula granules. We believe that the leading CXO industry WuXi Biologics (2269 HK) and WuXi AppTec (2359 HK) will still benefit from Increasing demand for innovative drug research and development. Considering the valuation factors, we have listed WuXi AppTec (2359 HK) as the top stock in the CXO sector for 2021, but we are still optimistic about WuXi Biologics (2269 HK). Both companies have increased by nearly 30% in the past month, and we recommend a fall Deploy at a later ***. ...

Trotz Pandemie Wachstum von WuXi Biologics beschleunigt https://www.ksta.de/wirtschaft/wuxi-biologics/trotz-pandemie--wachstum-von-wuxi-biologics-beschleunigt---37930034

https://www.spiegel.de/wirtschaft/corona-impfstoff-ehemaliges-bayer-werk-in-wuppertal-kann-produktion-erst-ende-2021-starten-a-0eaf2237-e39b-4102-ab21-09536c353960

WuXi Bio ist Anfang Januar auf T.witter gestartet: https://mobile.twitter.com/wuxibiologics

Bzw etwas ausführlicher dazu: https://m.jrj.com.cn/madapter/hk/2021/01/12123731675755.shtml

http://www.aastocks.com/tc/stocks/news/aafn-news/NOW.1068524/2 Morgan Stanley issued a research report that as the mainland government is determined to cut costs and encourage innovation, the threshold for the mainland pharmaceutical industry has increased in order to compete at the international level. The industry expects three companies to benefit from policy trends, and WuXi Biologics (02269.HK) is the industry's first choice this year,...

Global investors swoop in on WuXi Biologics shares as owner trims stakes in worlds largest post-IPO disposals https://amp.scmp.com/business/companies/article/3116760/global-investors-swoop-wuxi-biologics-shares-owner-trims-stakes • Nearly 142 million shares changed hands on Tuesday, almost triple the average daily volume last year, led by sale of stake by Biologics Holdings • Waiting in the wings to pick up Biologics’ shares were institutional investors including JPMorgan Chase and Los Angeles-based Capital Group ...

WuXi Biologics analyzes overseas acquisitions to boost profits after allotment, and enters the market when it is low, deploys target price and stop-loss price https://www.businesstimes.com.hk/articles/131355/%E8%97%A5%E6%98%8E%E7%94%9F%E7%89%A9%E9%85%8D%E8%82%A1%E5%BE%8C%E5%88%86%E6%9E%90-%E6%B5%B7%E5%A4%96%E6%94%B6%E8%B3%BC%E6%8E%A8%E5%8D%87%E7%9B%88%E5%88%A9-%E9%99%84%E7%9B%AE%E6%A8%99%E5%83%B9%E8%88%87%E6%AD%A2%E8%9D%95%E5%83%B9%E5%85%A5%E5%B8%82%E7%AD%96%E7%95%A5 WuXi Biologics (2269.HK) plans to spend 150 million euros to acquire MFG19, the facility asset of the German biopharmaceutical raw liquid manufacturing plant from Bayer. Taking into account the German drug production plant DP7 also purchased from Bayer in April this year, it shows that the group With regard to the determination of global expansion, the two factories are expected to be put into operation in 2021. WuXi Biologics' mid- and long-term investment can absorb while low  It is expected that WuXi Biologics sales will increase by 50% year-on-year in FY2021 and 40% to 50% in FY2022. It is expected that this acquisition can help WuXi Biologics improve its profitability in the long term. It is expected that WuXi Biologics sales will increase by 50% year-on-year in FY2021 and 40% to 50% in FY2022. It is expected that this acquisition can help WuXi Biologics improve its profitability in the long term. Recently, WuXi Biologics has placed shares. Although the stock price shows signs of retreat, there are buying orders and support at low levels, and medium and long-term investments can take advantage of the dip. • Target price: 120 yuan • Stop loss price: 90 yuan